Actively Recruiting
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Led by British Columbia Cancer Agency · Updated on 2026-02-02
100
Participants Needed
1
Research Sites
730 weeks
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
B
BC Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
CONDITIONS
Official Title
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men with favorable risk or intermediate-risk prostate cancer and an expected life expectancy of at least 10 years
- Clinical stage T1c to T2b, PSA less than 20, Gleason score less than 8
- ECOG performance status of 0 or 1
- Low tier intermediate-risk defined by one NCCN intermediate risk factor: either Gleason 7(3+4) with PSA less than 10 ng/ml or Gleason 6 with PSA between 10 and 20 ng/ml
- Extensive favorable-risk disease defined as clinical stage T1c to T2a, PSA less than 10, Gleason 6, 50% or more biopsy cores positive for cancer, and PSA density greater than 0.2 ng/cc
- Selected intermediate risk patients with T1c or T2a stage and PSA less than 10 with Gleason 4+3, or PSA between 10 and 20 with Gleason 3+4, or PSA 10-15 with Gleason 4+3 and less than 33% biopsy cores involved, or maximum tumor length in any core of 10 mm
- No prior androgen deprivation therapy
- Signed informed consent specific to the study
You will not qualify if you...
- Prior radical prostate surgery
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer
- Claustrophobia or inability to undergo MRI
- Unsuitable for general anesthesia
- Taking blood thinners that cannot be stopped for 24 hours
- Conditions that contraindicate radiotherapy such as systemic sclerosis or inflammatory bowel disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
British Columbia Cancer Center for the Southern Interior
Kelowna, British Columbia, Canada, V1Y 5L3
Actively Recruiting
Research Team
J
Juanita M Crook, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here